Analysed BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS) News Sources
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
31-03-2026
yahoo.com
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
26-02-2026
yahoo.com
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
20-02-2026
yahoo.com
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
19-02-2026
yahoo.com
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
14-11-2025
yahoo.com
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
14-08-2025
yahoo.com
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
08-08-2025
yahoo.com
BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
17-07-2025
yahoo.com
What is the current price of BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS)?
The current price of BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS) is $0.8421.
BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS) absolute price change since previous trading day?
The absolute price change of BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS) since the previous trading day is $-0.039022.
BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS) percentage price change since previous trading day?
The percentage price change of BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS) since the previous trading day is -4.4287%.
What is the most recent average sentiment score for BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS)?
The most recent average sentiment score for BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS) is 84 out of 100.
What is the most recent average sentiment for BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS)?
The most recent sentiment for BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS) is .
SEC-8K** Filing Available For BRAINSTORM CELL THERAPEUTICS (BCLI:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.